Welcome To Diurnal
Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.
Mission Statement
To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.
Latest News
-
15 Sep2020
Results for the year ended 30 June 2020
Successful commercialisation of Alkindi® underpins development of European commercial b
-
03 Sep2020
Diurnal signs two further marketing and distribution agreements for the Benelux Union and Switzerland
Advances Company’s strategy of partnering outside key European territories
-
27 Aug2020
Professor Richard Ross receives international honour from Endocrine Society
Professor Richard Ross, a founding Director of Diurnal and Chief Scientific Officer, has been recognised by the Endocrine Society’s 2021 Laureate Awards for Outstanding Innovation.